Natalizumab

Bevacizumab is a humanized monoclonal antibody that binds to all VEGF-A with high affinity and specificity.

Bevacizumab is a humanized monoclonal antibody that binds to all VEGF-A with high affinity and specificity.

Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab

Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab

Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab

Bexmarilimab (anti-STAB1) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab (anti-STAB1) is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab

Cabiralizumab (anti-CSF1R) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab (anti-CSF1R) enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab (anti-CSF1R) inhibits the activation of osteoclasts and blocks bone

Cabiralizumab (anti-CSF1R) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab (anti-CSF1R) enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab (anti-CSF1R) inhibits the activation of osteoclasts and blocks bone

Cabiralizumab (anti-CSF1R) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab (anti-CSF1R) enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab (anti-CSF1R) inhibits the activation of osteoclasts and blocks bone

Cabiralizumab (anti-CSF1R) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab (anti-CSF1R) enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab (anti-CSF1R) inhibits the activation of osteoclasts and blocks bone

An irreversible inhibitor of the chymotrypsin-like &beta5 subunit of the constitutive 20S proteasome (IC₅₀ = 5.2 nM) and the &beta5i subunit of the immunoproteasome 20Si (LMP7 IC₅₀ = 14 nM) with minimal cross reactivity to

The CFLAR/FLIP antibody from Proteintech is a Rabbit Polyclonal antibody to a Recombinant Protein of human CFLAR/FLIP. This antibody recognizes Human antigen.